Please assess the completion status of the following clinical trial:

Trial Title: Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must be ≥ 18 years old at the time of signing the ICF.~* The patient must have a histologically proven adenocarcinoma of the colon or rectum.~* The patient must have liver metastases non treatable with curative intent by surgical resection or local ablation at the time of registration.~* The patient must have measurable hepatic metastases defined by RECIST version 1.1 for solid tumors.~* The patient must have received one prior chemotherapy line for metastatic disease and have developed resistance or intolerance to this treatment.~* The patient must have an ECOG performance status 0 or 1.~* The patient must have the bone marrow reserve, hepatic and renal functions~Exclusion Criteria:~* Patients who are presenting evidence of ascites, cirrhosis, portal hypertension, main portal venous tumor involvement or thrombosis as determined by clinical or radiologic assessment.~* Patients who are planned to receive or concurrently receiving any non-cancer-directed investigational agent, or have received a non-cancer directed investigational agent within 3 weeks before the planned day for the first NKR-2 administration.~* Patients who are scheduled to receive concurrent growth factor (except erythropoietin), systemic steroid, other immunosuppressive therapy or cytotoxic agents (systemic or localized) other than the treatment authorized per protocol.~* Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration.~* Patients who have received a live vaccine ≤ 6 weeks prior to the planned day for the first NKR-2 administration.~* Patients with a family history of congenital or hereditary immunodeficiency.~* Patients with history of any autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose-level 1 (Type: EXPERIMENTAL): The dose-level 1 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
- Dose-level 2 (Type: EXPERIMENTAL): The dose-level 2 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
- Dose-level 3 (Type: EXPERIMENTAL): The dose-level 3 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).